Focusing first on the psychiatry space, Spektus Pharma combines the commercial acumen of Spektar with the pharmaceutical expertise of Altus to generate a portfolio of novel and differentiated Depression therapies that address the unmet needs of different patient segments. Each new product leverages Flexitab breakable extended-release technology to provide clinically meaningful benefits to the patient backed by new label claims. Supported by robust patents, Spektus products are designed to meet the commercial challenges facing global markets today while addressing the competing demands of patients, healthcare providers and payers. Spektus products are commercialized via regional licensing agreements with leading pharma companies around the world.
Company Details
- Employees
- 4
- Founded
- -
- Address
- The Unmet Needs Of Different Patient Segments. Each New Product Leverages Flexitab Breakable Extended-Release Technology To Provide Clinically Meaningful Benefits To The Patient Backed By New Label Claims. Supported By Robust Patents
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://spektuspharma.com
Spektus Pharma Questions
Spektus Pharma's website is http://spektuspharma.com
Spektus Pharma's LinkedIn profile is https://www.linkedin.com/company/spektus-pharma
Spektus Pharma has
4 employees.
View email and phone details for 4
employees at Spektus Pharma.
Spektus Pharma's industry is
Pharmaceutical Manufacturing
Spektus Pharma's top competitors are
Recipharm,
Sapir Venture Partners,
Tvm Capital Healthcare,
Candev, Inc.,
Access Mdk Inc.,
Dispersa Labs, Inc,
Biomedica Group,
Paladin Pharma,
Altus Drug Development,
Dispersa.
Spektus Pharma's categories are Pharmaceutical Manufacturing
Spektus Pharma's founding year is 2024
